Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease

Journal of Clinical Medicine

Alexis Bosman³  Michael J. Edel⁴  Gillian Blue²  Rodney J. Dilley¹  Richard P. Harvey³  David S. Winlaw² 

[1] Ear Science Institute Australia, Centre for Cell Therapy and Regenerative Medicine and School of Surgery, University of Western Australia, Nedlands WA 6009, Australia; E-Mail:;Heart Centre for Children, The Children’s Hospital at Westmead, Westmead NSW 2145, Australia; E-Mail:;Victor Chang Cardiac Research Institute, Lowy Packer Building, 405 Liverpool St., Darlinghurst NSW 2010, Australia; E-Mails:;St. Vincent’s Clinical School and School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington NSW 2052, Australia; E-Mail:

关键词: congenital heart disease;    hypoplastic left heart;    inducible pluripotential stem cells;    bioengineered myocardium;   

DOI  :  10.3390/jcm4040768

来源: mdpi

【 摘 要 】

Congenital heart disease places a significant burden on the individual, family and community despite significant advances in our understanding of aetiology and treatment. Early research in ischaemic heart disease has paved the way for stem cell technology and bioengineering, which promises to improve both structural and functional aspects of disease. Stem cell therapy has demonstrated significant improvements in cardiac function in adults with ischaemic heart disease. This finding, together with promising case studies in the paediatric setting, demonstrates the potential for this treatment in congenital heart disease. Furthermore, induced pluripotent stems cell technology, provides a unique opportunity to address aetiological, as well as therapeutic, aspects of disease.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.